Kathy D. Miller
Indiana University
387 Papers
2.8K Citations
Kathy D. Miller is an academic researcher from Indiana University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 65, co-authored 343 publications. Previous affiliations of Kathy D. Miller include Regenstrief Institute & American Society of Clinical Oncology.
Chat about Author
Papers
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller,Molin Wang,Julie Gralow,Maura N. Dickler,Melody A. Cobleigh,Edith A. Perez,Tamara Shenkier,David Cella,David Cella,Nancy E. Davidson +9 more
TL;DR: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with pac litaxel alone.
3.2K
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
Frank A. Scappaticci,Jamey R. Skillings,S. N. Holden,Hans-Peter Gerber,Kathy D. Miller,Fairooz F. Kabbinavar,Emily K. Bergsland,James Ngai,Eric Holmgren,Jiuzhou Wang,Herbert Hurwitz +10 more
TL;DR: Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with an increased risk of arterial thromboembolism but not venous thrombosis, and Baseline or on-study aspirin use wasassociated with modest increases in grade 3 and 4 bleeding events.
971
NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4
Gregory M. Helbig,Kent W. Christopherson,Poornima Bhat-Nakshatri,Suresh M. Kumar,Hiromitsu Kishimoto,Kathy D. Miller,Hal E. Broxmeyer,Harikrishna Nakshatri +7 more
TL;DR: It is demonstrated that NF-κB regulates the motility of breast cancer cells by directly up-regulating the expression of CXCR4 and the SDF-1α-mediated migration is observed with cancer cells that metastasized to the lungs.
690
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Bryan P. Schneider,Molin Wang,Milan Radovich,George W. Sledge,Sunil Badve,Ann D. Thor,David A. Flockhart,Bradley A. Hancock,Nancy E. Davidson,Julie R. Gralow,Maura N. Dickler,Edith A. Perez,Melody A. Cobleigh,Tamara Shenkier,Susan M. Edgerton,Kathy D. Miller +15 more
TL;DR: The data support an association between VEGF genotype and median OS as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer.
A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer
Melody A. Cobleigh,Virginia K. Langmuir,George W. Sledge,Kathy D. Miller,Latrice Haney,William Novotny,James D. Reimann,Amy Vassel +7 more
TL;DR: The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable, and these data support the initiation of trials in metastatic breast cancer combining bevacszumab with chemotherapy.
525